NCT02996721CompletedPhase 4
A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients
A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients (The TARGET-D Study)
Source: ClinicalTrials.gov · Last updated 5 Nov 2026
Brief summary (registry, in English)
This study evaluates whether achieving 25-hydroxyvitamin D (25\[OH\] Vit D) levels (\>40 ng/mL) among myocardial infarction patients will result in a reduction of cardiovascular-related adverse events. Half of the patients will be randomized to receive standard of care and half will receive clinical management of 25\[OH\] Vit D levels.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 634 (actual)
- First submitted
- 15 Dec 2016
- Start date
- 3 Apr 2017
- Primary completion date
- 30 Mar 2025
- Lead sponsor
- Intermountain Health Care, Inc.
- Diseases
- Heart failure, Coronary artery disease
- NCT number
- NCT02996721
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 634
- From 3 Apr 2017 to the primary completion date, 30 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of previous vitamin D supplementation of \>1000 IU daily within the past 3 months (i.e., \>40% of the days during the past 3 months).
- Subject participation in previous investigational interventional studies within 30 days of the current study.
Other illness
- Hypersensitivity to vitamin D products
- Systemic disease (including terminal cancer, cirrhosis, end stage COPD, etc) with a reduced (\<12 months) life expectancy
- History of psychiatric illness/condition that would interfere with their ability to understand or complete the requirements of the study, a condition that in the opinion of the investigator or their designee places the subject at an unacceptable risk as a participant.
Lab values
- Hypercalcemia (calcium levels \>10.6 mg/dL)
Other
- Pregnant and/or lactating women and women of child bearing potential who are not using acceptable means of contraception as determined by the clinical investigators.
Who the study is looking for
- Patients, both male and female, \>18 years old
- Undergone angiography for a MI (troponin positive \[\>0.04 ng/mL\] and ACS diagnosis) within the past month
- Receive follow-up care at an Intermountain Healthcare facility
- Not taking or taking \<1000 IU of vitamin D daily within the last 3 months
- Willing to provide informed consent and participate in follow-up visits
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Intermountain Medical Center Coordinator of this site? Confirm its status | Murray | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.